Mental war among domestic companies facing Viread’s salt-modified products
While the gigantic hepatitis B therapy, ‘Viread(tenofovir disoproxil fumarate)’ is expected to be expired in its substance patent next year, competition among domestic companies have already started over follow-up products.
A part of pharmaceutical companies have also taken legal actions as regi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
